The Clinical Utility of Molecular Imaging in COVID-19: An Update

Elsevier

Available online 22 September 2022

Seminars in Nuclear MedicineAbstract

The novel pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first discovered in Wuhan, China in late 2019 with Coronavirus disease 2019 (COVID-19) declared a global pandemic in March 2020. Primarily involving the lungs, conventional imaging with chest radiography and CT can play a complementary role to RT-PCR in the initial diagnosis, and also in follow up of select patients. As a broader understanding of the multi-systemic nature of COVID-19 has evolved, a potential role for molecular imaging has developed, that may detect functional changes in advance of standard cross-sectional imaging. In this review, we highlight the evolving role of molecular imaging such as fluorine-18 (18F) fluorodeoxyglucose (FDG) with PET/CT and PET/MRI in the evaluation of both pulmonary and extra-pulmonary COVID-19, ventilation and perfusion scan with SPECT/CT for thromboembolic disease, long term follow-up of COVID-19 infection, and COVID-19 vaccine-related complications.

Keywords

COVID-19

PET/CT

molecular imaging

V/Q

pulmonary embolism

nuclear cardiology

SPECT/CT

COVID-19 vaccination

View full text

© 2022 Elsevier Inc. All rights reserved.

留言 (0)

沒有登入
gif